In contrast, estrogen-containing contraceptives carry a higher baseline risk for venous thromboembolism and potential CYP3A4-mediated interactions, so they are generally less appropriate in women receiving BTK or BCL-2 inhibitors or in those with additional VTE risk factors [3, 10–15, 17, 20]. This evidence concerns the gene BCL2 and venous thromboembolism.